



Catabasis Pharmaceuticals to Present at Oppenheimer's 27th Annual Healthcare Conference

March 15, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 15, 2017-- [Catabasis Pharmaceuticals, Inc.](http://www.catabasis.com) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate and pipeline overview at Oppenheimer's 27th Annual Healthcare Conference on March 22, 2017 at 3:20pm ET at the Westin New York Grand Central Hotel in New York City, NY.

A webcast of the presentation will be available in the Investors section of the Company's website, www.catabasis.com, and will be archived for 30 days following the presentation.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company's drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170315005034/en/>

Source: Catabasis Pharmaceuticals, Inc.

Corporate and Media Contact
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com